AMGN stock forecast: what analysts expect
Wall Street analysts covering Amgen Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $381.59 — -8.3% versus the last price of $416.18. Targets reflect analyst opinion, not a guarantee.
AMGN historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in AMGN.
AMGN annual returns by year
Congress trading in AMGN
27 members of Congress have disclosed trading AMGN — 29 purchases and 17 sales worth an estimated $582,000. Most recent disclosure: Jun 5, 2026.
See who in Congress traded AMGN →Insider activity in AMGN
AMGN's own executives and directors have made 0 open-market purchases ($0) and 4 sales ($2.8M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 6, 2026.
| Aug 6, 2026 | Miller Derek | SVP, Human Resources | Sell | $832,864 |
| Aug 6, 2026 | Miller Derek | SVP, Human Resources | Sell | $733,033 |
| Aug 6, 2026 | Grygiel Nancy A. | SVP & CCO | Sell | $792,255 |
| Aug 6, 2026 | Grygiel Nancy A. | SVP & CCO | Sell | $402,160 |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Key Statistics
AMGN in plain English
- P/E ratio (25.7) — how many dollars you pay for each $1 of AMGN's yearly profit. That's a fairly normal range.
- ROE (91.47%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (22.95%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.43%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
AMGN stock: frequently asked questions
What is Amgen Inc.'s stock price today?
Amgen Inc. (AMGN) last traded at $416.18 on the NASDAQ. Over the past 52 weeks the stock has traded between $269.77 and $421.79.
Is AMGN stock a buy or a sell?
Wall Street analysts' consensus rating on AMGN is "Buy", with an average 12-month price target of $381.59 — about -8.3% versus the current price of $416.18. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in AMGN 10 years ago be worth today?
A $1,000 investment in Amgen Inc. made 10 years ago would be worth about $3,278 today (dividends reinvested) — a total return of 228%, or 12.6% per year.
Does AMGN pay a dividend?
Yes. Amgen Inc. currently pays a dividend yielding about 2.43% per year at today's share price.
What is AMGN's P/E ratio?
AMGN trades at a trailing price-to-earnings ratio of 25.7, and 17.2 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade AMGN stock?
Yes — 27 members of Congress have disclosed trades in AMGN under the STOCK Act, totaling 29 purchases and 17 sales worth an estimated $582,000.
What is Amgen Inc.'s ticker symbol?
Amgen Inc. trades under the ticker symbol AMGN on the NASDAQ.
Compare AMGN with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.